Automera is an early-stage company focused on the development of a novel therapeutic approach via autophagy-based targeted protein degradation. Automera aims to leverage its unique understanding of autophagy, drug development capabilities, and access to quantum chemistry and generative AI-enabled insights to enhance its drug development programs. Automera’s AUTAC platform has broad potential across cancer and other disease areas, with oncology being the initial lead program. The company was founded by co-founders Associate Professor Michael Lazarou, Loong Wang, and Taiyang Zhang at Talo Labs Pte Ltd.

Disclaimer : All logos and trademarks on this website are the property of their respective owners. The information on this website is not a medical or investment related advice. The information about the company might not reflect the most current or accurate information. Please refer to the company's respective website for the most accurate information.

© 2023-24 DxMultiomics. All rights reserved.